H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice.
Biomed Pharmacother
; 176: 116781, 2024 Jul.
Article
de En
| MEDLINE
| ID: mdl-38805966
ABSTRACT
Influenza A virus causes numerous deaths and infections worldwide annually. Therefore, we have considered nanobodies as a potential treatment for patients with severe cases of influenza. We developed a nanobody that was expected to have protective efficacy against the A/California/04/2009 (CA/04; pandemic 2009 flu strain) and evaluated its therapeutic efficacy against CA/04 in mice experiments. This nanobody was derived from the immunization of the alpaca, and the inactivated CA/04 virus was used as an immunogen. We successfully generated a nanobody library through bio-panning, phage ELISA, and Bio-layer interferometry. Moreover, we confirmed that administering nanobodies after lethal doses of CA/04 reduced viral replication in the lungs and influenza-induced clinical signs in mice. These research findings will help to develop nanobodies as viral therapeutics for CA/04 and other infectious viruses.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Infections à Orthomyxoviridae
/
Sous-type H1N1 du virus de la grippe A
/
Anticorps à domaine unique
Limites:
Animals
Langue:
En
Journal:
Biomed Pharmacother
Année:
2024
Type de document:
Article